Turning Point Therapeutics, Inc. announced the addition of Barbara Bodem to its board of directors. Ms. Bodem brings extensive operating and board experience, and has been appointed to chair the audit committee. In addition, Garry Nicholson, an existing member of the Turning Point board, has been named interim board chair while a formal search for a permanent chair is ongoing. Former board chair Sheila Gujrathi, M.D., and Jacob Chacko, M.D. have stepped down from the board concurrently with these changes. Ms. Bodem is CFO of Hill-Rom Holdings, Inc. During her more than 30-year career, she also served as senior vice president of Finance at Mallinckrodt Pharmaceuticals, vice president of Global Commercial Finance at Hospira Inc., and in a variety of finance roles for over 15 years at Eli Lilly in both the U.S. and U.K., including serving as CFO of Lilly Oncology. She previously served on the board of Invacare Corp.